Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

European Journal of Pharmacology

Volumn 353, Issue 2-3, 1998, Pages 191-206

  Klitgaard, Henrik ^a   Matagne, Alain ^a   Gobert, Jean ^a   Wülfert, Ernst ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Anticonvulsant; Antiepileptic; Epilepsy; Levetiracetam; Seizure; Ucb L059

Indexed keywords

4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTICONVULSIVE AGENT; APOMORPHINE; BICUCULLINE; CAFFEINE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FLUMAZENIL; GABAPENTIN; KAINIC ACID; LAMOTRIGINE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; PILOCARPINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG METABOLISM; ELECTRIC SHOCK; EPILEPSY; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION;

AMYGDALA; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CARBOLINES; CONVULSANTS; DIAZEPAM; DISEASE MODELS, ANIMAL; ELECTROCONVULSIVE THERAPY; EPILEPSY; EXCITATORY AMINO ACID AGONISTS; FLUMAZENIL; KINDLING, NEUROLOGIC; MALE; MICE; PENTYLENETETRAZOLE; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SEIZURES;

EID: 0032563178     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00410-5     Document Type: Article

References (40)

1. Birnstiel, S., Wülfert, E., Beck, S.G., 1997. Levetiracetam (L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn-Schmiedeberg's Arch. Pharmacol. 356, 611-618.
2. Czuczwar, S.J., Meldrum, B., 1982. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur. J. Pharmacol. 83, 335-338.
3. De Deyn, P.P., Kabatu, H., D'Hooge, R., Mori, A., 1992. Protective effect of ucb L059 against postural stimulation-induced seizures in EL Mice. Neuroscience 18, 187-192, (Suppl. 2).
4. Gale, K., 1986. Role of the Substantia Nigra in GABA-mediated anticonvulsant actions. In: Delgado-Escueta, Ward, Woodbury, Porter (Eds.), Advances in Neurology 44, 343-364.
5. Goddard, G.V., McIntyre, D.C., Leech, C.K., 1969. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 25, 295-330.
6. Gower, A.J., Matagne, A., 1994. Levetiracetam (ucb L059): anticonvulsant effects are mediated by the parent compound. Epilepsia 35, 75, (Suppl. 7).
7. Gower, A.J., Noyer, M., Verloes, R., Gobert, J., Wülfert, E., 1992. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222, 193-203.
8. Gower, A.J., Hirsch, E., Boehrer, A., Noyer, M., Marescaux, C., 1995. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22, 207-213.
9. Haigh, J.R.M., Feely, M., 1988. Tolerance to the anticonvulsant effect of benzodiazepines. Trends Pharmacol. Sci. 9, 361-366.
10. Hönack, D., Löscher, W., 1995. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36, 763-771.
11. Irwin, S., 1968. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (Berlin) 13, 222-257.
12. Klitgaard, H., Knutsen, L.J.S., Thomsen, C., 1993. Contrasting effects of adenosine A1 and A2 receptor ligands in different chemoconvulsive rodent models. Eur. J. Pharmacol. 242, 221-228.
13. Little, H.J., Gale, R., Sellars, N., Nutt, D.J., Taylor, S.C., 1988. Chronic benzodiazepine treatment increases the effects of the inverse agonist FG 7142. Neuropharmacology 27, 383-389.
14. Löscher, W., Hönack, D., 1991. Anticonvulsant and behavioural effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 256, 432-440.
15. Löscher, W., Hönack, D., 1993. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232, 147-158.
16. Löscher, W., Schmidt, D., 1994. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Res. 17, 95-134.
17. Löscher, W., Jäckel, R., Czuczwar, S.J., 1986. Is amygdala kindling in rats a model for drug-resistant partial epilepsy?. Exp. Neurol. 93, 211-226.
18. Löscher, W., Hönack, D., Blombs-Funke, P., 1996. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res. 735, 208-216.
19. Löscher, W., Hönack, D., Rundfeldt, C., 1998. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 284, 474-479.
20. 3 in vivo. Eur. J. Pharmacol. 286, 321-325.
21. A receptor associated epileptiform effect of bicuculline in rat hippocampus. Br. J. Pharmacol. 122, 1146-1150.
22. Matagne, A., Klitgaard, H., 1998. Validation of corneally-kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 31, 59-71.
23. Nadler, J.V., 1981. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci. 29, 2031-2042.
24. Noyer, M., Gillard, M., Matagne, A., Hénichart, J.P., Wülfert, E., 1995. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286, 137-146.
25. Paxinos, G., Watson, C., 1982. The Rat Brain in Stereotaxic Coordinates. Academic Press, Australia.
26. Petersen, E.N., 1983. DMCM: a potent convulsive benzodiazepine receptor ligand. Eur. J. Pharmacol. 94, 117-124.
27. Racine, R.J., 1972. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32, 295-299.
28. Siegel, S., Castellan, N.J., 1988. Nonparametric Statistics for the Behavioral Sciences, 2nd edn. McGraw-Hill International Editions.
29. Sills, G.J., Leach, J.P., Fraser, C.M., Forrest, G., Patsalos, P.N., Brodie, M.J., 1997. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur. J. Pharmacol. 325, 35-40.
30. Silver, J.M., Shin, C., McNamara, J.O., 1991. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann. Neurol. 29, 356-363.
31. Steppuhn, K.G., Turski, L., 1993. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 265, 1063-1070.
32. Sveinbjornsdottir, S., Sander, J.W.A.S., Upton, D., Thompson, P.J., Patsalos, P.N., Hirt, D., Emre, M., Lowe, D., Duncan, J.S., 1993. The excitatory amino acid antagonist D-CPPene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16, 165-174.
33. Turski, W.A., Cavalheiro, E.A., Schwarz, M., Czuczwar, S.J., Kleinrok, Z., Turski, L., 1983. Limbic seizures produced by pilocarpine in rats: a behavioural, electroencephalographic and neuropathological study. Behav. Brain Res. 9, 315-336.
34. Turski, L., Meldrum, B.S., Cavalheiro, E.A., Calderazzo-Filho, L.S., Bortolotto, Z.A., Ikonomidou-Turski, C., Turski, W.A., 1987. Paradoxial anticonvulsant activity of the excitatory amino acid N-methyl-D-aspartate in the rat caudate-putamen. Proc. Natl. Acad. Sci. USA 84, 1689-1693.
35. Turski, L., Cavalheiro, E.A., Bortolotto, Z.A., Ikonomidou-Turski, C., Kleinrok, Z., Turski, W.A., 1988. Dopamine-sensitive anticonvulsant site in the rat striatum. J. Neurosci. 8, 4027-4037.
36. Turski, L., Andrews, J.S., Löschmann, P., Bressler, K., Bortolotto, Z.A., Calderazzo, L.S., Cavalheiro, E.A., 1990. Substantia nigra regulates action of antiepiletic drugs. Brain Res. 520, 232-239.
37. Turski, L., Jacobsen, P., Honoré, T., Stephens, D.N., 1992. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline. J. Pharmacol. Exp. Ther. 260, 742-747.
38. Verloes, R., Scotto, A.-M., Gobert, J., Wülfert, E., 1988. Effects of nootropic drugs in a scopolamine-induced amnesia model in mice. Psychopharmacology 95, 226-230.
39. Waszczak, B.L., Lee, E.K., Walters, J.R., 1986. Effects of anticonvulsant drugs on substantia nigra pars reticulata neurons. J. Pharmacol. Exp. Ther. 239, 606-611.
40. Woods, J.H., Katz, J.L., Winger, G., 1995. Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs. In: Bloom, F.E., Kupfer, D.J., (Eds.), Psychopharmacology, The Fourth Generation of Progress. Raven Press, New York, pp. 1777-1791.